# Cardiosense

> Cardiosense is a Chicago-based health-tech company building an AI platform that turns raw physiological signals into clinical intelligence for heart failure. Its FDA-cleared CardioTag wearable simultaneously captures ECG, PPG and seismocardiogram (SCG) signals, and its machine-learning algorithms estimate pulmonary capillary wedge pressure (PCWP) - a key measure of cardiac filling pressure - noninvasively, so clinicians can spot a worsening heart before it lands a patient in the hospital.

- **Founded:** 2017
- **Headquarters:** Chicago, Illinois, United States
- **Founders:** Amit Gupta (Co-founder, Chief Strategy Officer (founding CEO)), Andrew Carek (Co-founder, Chief Technical Officer), Omer Inan (Co-founder, Chief Scientific Officer), Mozziyar Etemadi (Co-founder, Head of AI)
- **Team size:** ~38 employees
- **Products:** CardioTag, PCWP Analysis Software, Physiological waveform AI platform
- **Notable:** FDA 510(k) clearance for the CardioTag device (July 2025), FDA Breakthrough Device Designation for its early heart failure detection algorithm, Raised $15.1M Series A in December 2022

## Products & services

- **CardioTag** — An FDA 510(k)-cleared, noninvasive wearable sensor - the company says it is the first to simultaneously capture high-fidelity electrocardiogram (ECG), photoplethysmogram (PPG) and seismocardiogram (SCG) signals from a single chest-worn device.
- **PCWP Analysis Software** — Machine-learning software that converts CardioTag's raw waveforms into a noninvasive estimate of pulmonary capillary wedge pressure (PCWP), the cardiac filling-pressure measure traditionally obtained via right heart catheterization.
- **Physiological waveform AI platform** — The underlying platform combining multi-sensor hardware, signal processing and deep learning to develop digital biomarkers that detect early cardiovascular changes and guide personalized therapy.

## Achievements

- FDA 510(k) clearance for the CardioTag device (July 2025)
- FDA Breakthrough Device Designation for its early heart failure detection algorithm
- Raised $15.1M Series A in December 2022
- SEISMIC-HF I study (310 HFrEF patients) validating noninvasive PCWP estimation, published in JACC: Heart Failure
- Presented new SEISMIC-HF I analyses at TCT 2025 and AHA Scientific Sessions 2025
- Selected into the MedTech Innovator and Portal Innovations programs

## Latest updates

- **2025-11** — Presented a new analysis of the SEISMIC-HF I study validating its AI algorithm for noninvasive PCWP assessment at the American Heart Association 2025 Scientific Sessions.
- **2025-10** — Presented new clinical analysis of SEISMIC-HF I data on AI-enabled volume assessment in heart failure at TCT 2025.
- **2025-07** — Received FDA 510(k) clearance for the CardioTag device, clearing the way for commercial deployment.
- **2022-12** — Closed $15.1M Series A co-led by Broadview Ventures and Hatteras Venture Partners.

## Links

- Website: https://cardiosense.com
- LinkedIn: https://www.linkedin.com/company/cardiosense
- Twitter/X: https://twitter.com/cardiosenseinc

---

Profile page: https://yespress.io/cardiosense
Published by YesPress — https://yespress.io
Last updated: 2026-06-15